http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-073659-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| filingDate | 2009-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec19aee5935a587d598adc1fadf338ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d36438eea74fd177a34e8914e7482c05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd04f3d42db7817cc68425a08998fd2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d56fd245325aa48b9acc792c55f3913 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13c495f21ec48685073d4bdebddf384c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cca10ab4f8b42af337932a285a2d2b29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12b90dfeaac251ec347b834d336bbd0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b417eae408f5893bc46537002953cdd |
| publicationDate | 2010-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-073659-A1 |
| titleOfInvention | INHIBITING COMPOUNDS OF HEPATITIS C |
| abstract | The compounds are useful as inhibitors of HCV NS3 protease for the treatment of a viral infection of hepatitis C. Claim 1: A compound characterized in that it has the formula (1), and a racemate, diastereoisomer or optical isomer thereof: in the R3 is C2-8 alkyl, C3-7 cycloalkyl or C1-3 alkyl-C3-7 cycloalkyl, wherein each of said alkyl, cycloalkyl and alkylcycloalkyl groups may be mono-, di- or tri-substituted with C1-alkyl -4; L0 is halogen, C1-4 alkyl, -OH, -O-C1-4 alkyl, -NH2, -N C1-4 alkyl or -N (C1-4 alkyl) 2; L1 is halogen, C1-4 alkyl, -O-C1-4 alkyl, -S-C1-4 alkyl, -SO-C1-4 alkyl or -SO2-C1-4 alkyl, where each of said alkyl groups is optionally substituted with one to three halogen atoms; R2 is -NR22COR20, -NR22COOR20, -NR22R21 or-NR22CONR21R23, where R20 is C1-6 alkyl, C3-7 cycloalkyl or C1-4 alkyl-C3-7 cycloalkyl, wherein said alkyl, cycloalkyl or alkyl-cycloalkyl may be mono- , di- or tri-substituted with C1-3 alkyl or -O-C1-3 alkyl; R21 is H or R20 as defined above, R22 and R23 are independently H or methyl, R1 is C1-4 alkyl, C2-4 alkenyl or C3-7 cycloalkyl; Rc is hydroxy or NHSO2RS where Rs is C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, aryl or Het; each optionally being mono-, di- or tri-substituted with substituents selected from halogen, hydroxy, cyano, C1-4 alkyl, -O-C1-6 alkyl, -CO-NH2, -CO-NH-C1 alkyl -4, -CO-N (C1-4 alkyl) 2, -NH2, -NH-C1-4 alkyl and -N (C1-4 alkyl) 2, where C1-4 alkyl and O- C1-6 alkyl are optionally substituted with one to three halogen atoms; B is C (= O) -R4 where R4 is C1-6 alkyl, C3-7 cycloalkyl, C1-4 alkyl-C3-7 cycloalkyl, C3-7 cycloalkenyl, C1-4 alkyl-C3-7 cycloalkenyl, Het, aryl , C1-4-Het alkyl or C1-4-aryl alkyl; all of them being optionally substituted 1 to 3 times with C1-4 alkyl, hydroxy, O-C1-4 alkyl or halogen; or B is aryl or Het, optionally mono-, di- or tri-substituted with halogen, hydroxy, C1-6 alkyl, O-C1-6 alkyl, O-aryl, O-Het, S-C1-6 alkyl, - CO- C1-6 alkyl, -CO-NH2, -CO-NH-C1-4 alkyl, -CO-N (C1-4 alkyl) 2, -NH2, -NH-C1-4 alkyl) and -N (alkyl C1-4) 2, wherein said alkyl and O-alkyl groups may be optionally substituted with 1 to 3 halogen atoms; and where Het is a 4 to 7 membered heterocycle, saturated, unsaturated or aromatic having 1 to 4 heteroatoms, each independently selected from O, N and S, or a 7 to 14 member heteropolyclo, saturated, unsaturated or aromatic , which has, when possible, 1 to 5 heteroatoms, each independently selected from O, N and S, where each heteroatom of N, independently and when possible, can exist in an oxidized state so that it is further attached to an oxygen atom to form an N-oxide group and where each heteroatom of S, independently and whenever possible, can exist in an oxidized state so that it is further attached to one or two oxygen atoms to form the SO or SO2 groups . or a pharmaceutically acceptable salt or ester thereof. |
| priorityDate | 2008-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.